SS18 and synovial sarcoma: We find that exposure of synovial sarcoma cells to FK228, a potent HDAC1/2 inhibitor (Furumai et al., 2002), leads to the induction of FYN mRNA and protein expression which could render synovial sarcoma cells resistant to growth inhibition after loss of SS18-SSX function.